Is Alpha-B Crystallin an Independent Marker for Prognosis in Lung Cancer?

Campbell-Lloyd, Andrew J. M., Mundy, Julie, Deva, Rajeev, Lampe, Guy, Hawley, Carmel, Boyle, Glen, Griffin, Rayleene, Thompson, Charles and Shah, Pallav (2013) Is Alpha-B Crystallin an Independent Marker for Prognosis in Lung Cancer?. Heart Lung and Circulation, 22 9: 759-766. doi:10.1016/j.hlc.2013.01.014

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Campbell-Lloyd, Andrew J. M.
Mundy, Julie
Deva, Rajeev
Lampe, Guy
Hawley, Carmel
Boyle, Glen
Griffin, Rayleene
Thompson, Charles
Shah, Pallav
Title Is Alpha-B Crystallin an Independent Marker for Prognosis in Lung Cancer?
Journal name Heart Lung and Circulation   Check publisher's open access policy
ISSN 1443-9506
1444-2892
Publication date 2013-09-01
Year available 2013
Sub-type Article (original research)
DOI 10.1016/j.hlc.2013.01.014
Open Access Status Not yet assessed
Volume 22
Issue 9
Start page 759
End page 766
Total pages 8
Place of publication Chatswood, NSW, Australia
Publisher Elsevier Australia
Language eng
Subject 2740 Pulmonary and Respiratory Medicine
2705 Cardiology and Cardiovascular Medicine
Abstract Background: Alpha B-crystallin (CRYAB) is an oncogene that increases tumour survival by promoting angiogenesis and preventing apoptosis. CRYAB is an independent prognostic marker in epithelial tumours including head and neck squamous cell carcinoma and breast cancer where it is predictive of nodal status and associated with poor outcome. We explored the role of CRYAB in non-small-cell lung cancer (NSCLC). Methods: Immunohistochemical analysis was performed on 50 samples. Following staining with anti-alpha-B crystallin antibody, a blinded pathologist scored samples for nuclear (N) and cytoplasmic (C) staining intensity. Analysis was performed using Cox's proportional hazards model. Results: There were 32 adenocarcinomas and 18 squamous cell carcinomas. The median tumour size was T2, grade 2 moderately differentiated, and 10 patients had nodal spread. Recurrence was seen in 22 patients (46%). Mortality was 48%, with median time to mortality 871 days. N staining was detected in eight samples (16%), and C staining in 20 (40%), with both N and C staining positive in five (10%). Staining for CRYAB predicted neither recurrence (N stain p= 0.78, C stain p= 0.38) nor mortality (N stain p= 0.86, C stain p= 0.66). Conclusion: CRYAB did not predict outcomes in patients treated for NSCLC. Larger studies are required to validate this finding.
Keyword Lung cancer
Markers
Outcomes
Induced Apoptosis
Expression
Activation
Carcinoma
Caspase-3
Involvement
Inhibitor
Survival
Pathway
Tumors
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 10 Nov 2013, 10:25:50 EST by System User on behalf of School of Medicine